Finance

Lists
Why is NVAX down 2.91%?
Dive Deeper
NVAX:NASDAQ
Novavax Inc
$8.50
-2.91%
(-0.26) 1D
Nov 13, 3:47:11 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NVAX...
Open
$8.77
High
$9.74
Low
$8.35
Mkt. cap
1.41B
Avg. vol.
8.28M
Volume
3.60M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$0.46
Beta
2.65
Shares outstanding
165.01M
No. of employees
749
Open
$8.77
High
$9.74
Low
$8.35
Mkt. cap
1.41B
Avg. vol.
8.28M
Volume
3.60M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$0.46
Beta
2.65
Shares outstanding
165.01M
No. of employees
749
News stories
From web sources and news partners
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorHealth Care
IndustryBiotechnology
Websitenovavax.com
Analyst ratings
Based on 5 analysts giving stock ratings to NVAX in the past 3 months
Hold
Buy
3
Hold
0
Sell
2
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for NVAX in the last 3 months.
Highest
Current $8.50
$19.00 (+123.40%)
Average
$13.60 (+59.91%)
Lowest
$7.00 (-17.70%)
Analyst
Recommendation
Action
Price target
Projected
Date
Pete Stavropoulos
Cantor Fitzgerald
Buy
Maintained
$18.00
+111.6%
11/05/2026
Mayank Mamtani
B. Riley Securities
Buy
Initiated
$16.00
+88.1%
11/06/2026
Thomas Shrader
BTIG
Buy
Maintained
$19.00
+123.4%
11/05/2026
Alec Stranahan
Bank of America Securities
Sell
Reiterated
$7.00
-17.7%
11/06/2026
Geoff Meacham
Citi
Sell
Maintained
$8.00
-5.9%
10/16/2026
Unknown Analyst
Cantor Fitzgerald
Buy
Maintained
$18.00
+111.6%
08/06/2026
Chris LoBianco
TD Cowen
Hold
Reiterated
$9.00
+5.8%
08/04/2026
Steve Scala
TD Cowen
Hold
Reiterated
$9.00
+5.8%
05/06/2026
Sean Lee CFA
H.C. Wainwright
Buy
Reiterated
$16.00
+88.1%
04/21/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
-$0.19 / -$0.42
+54.76%beat
Revenue / Est. (USD)
68.30M / 50.42M
+35.45%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
147.14M
139.51M
56.70M
68.30M
Cost of goods sold
135.96M
112.43M
72.29M
67.46M
Cost of revenue
135.96M
112.43M
72.29M
67.46M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-9.76M
37.12M
35.21M
29.02M
Operating expense
-9.76M
37.12M
35.21M
29.02M
Total operating expenses
126.20M
149.54M
107.50M
96.48M
Operating income
20.94M
-10.03M
-50.81M
-28.18M
Other non operating income
53.37M
525.00K
119.00K
328.00K
EBT including unusual items
17.90M
-8.51M
-51.68M
-29.65M
EBT excluding unusual items
29.41M
-3.11M
-47.58M
-26.55M
Income tax expense
376.00K
985.00K
1.71M
1.72M
Effective tax rate
2.10%
-11.58%
-3.31%
-5.81%
Other operating expenses
-
-
-
-
Net income
17.53M
-9.49M
-53.39M
-31.38M
Net profit margin
11.91%
-6.80%
-94.16%
-45.94%
Earnings per share
0.11
-0.06
-0.32
-0.19
Interest and investment income
-
7.10M
6.90M
6.20M
Interest expense
-27.99M
-4.90M
-5.69M
-5.40M
Net interest expenses
-27.99M
2.20M
1.21M
799.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
26.06M
-6.97M
-47.75M
-25.13M
Gain or loss from assets sale
807.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps